Boston Pharmaceuticals represents a new pharmaceutical company model, providing a bridge to value realization for early-stage clinical development programs. By offering strategic partnership options to biotech and pharmaceutical companies, our goal is to enable differentiated, under-resourced therapeutics to be developed and made available to patients with unmet medical needs. We focus primarily on clinical development from IND through Phase 2 clinical proof-of-concept (PoC). Our team leverages an average of over 20 years of drug development experience and a broad network of external resources to design and execute highly efficient, definitive clinical PoC programs, enabling our partners to advance into pivotal trials with a high probability of success. We are actively investing a significant long-term base of capital to build a carefully constructed portfolio of clinical candidates across a broad array of mechanisms and therapeutic targets. We were launched in late 2015 and are funded by Gurnet Point Capital, a $2 billion healthcare private equity fund.
Our Business Model
We seek to acquire drug development programs from IND enabling through early Phase 2, and ultimately license or sell those that reach clinical PoC in order to create value for our organization and our partners.
We apply a rigorous, data-driven and objective approach to drug development, incorporating interim analyses and milestones in order to de-risk our investments before major capital commitments are made. Our team of scientists and clinicians have expertise across multiple disease areas, mechanisms, and molecule types. The clinical, pharmaceutical, and oversight strategies are led by our core team and we manage all work through a global network of exceptional partners and consultants.